Myelodysplastic Syndrome Clinical Trials in Duarte, California

13 studies are recruiting for myelodysplastic syndrome in Duarte, California right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions

    The main aim of this study is to assess how elritercept works in lowering the need for RBC (red blood cell) transfusions and how safe elritercept is when compared with epoetin alfa. Other aims are to learn if elritercept improves tiredness as reported by participants without needing RBC transfusion…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    City of Hope - Comprehensive Cancer Center (CCC), Duarte, California
    Locations
    162 in total
    Run by
    Takeda

    See if you can join NCT07422480 on ClinicalTrials.gov

  2. Total Marrow and Lymphoid Irradiation in Combination With Fludarabine and Melphalan as Conditioning for Allogeneic Peripheral Blood Stem Cell Hematopoietic Cell Transplant in Older Patients With Refractory and Relapsed Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome

    This phase II trial tests the effect of total marrow and lymphoid irradiation (TMLI) in combination with fludarabine and melphalan as conditioning regimen in older patients with acute myeloid leukemia or high-risk myelodysplastic syndrome that has not responded to previous treatment (refractory) an…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    City of Hope Medical Center, Duarte, California
    Run by
    City of Hope Medical Center

    See if you can join NCT07582172 on ClinicalTrials.gov

  3. 225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome

    This phase I trial tests the safety, side effects, best dose, and effectiveness of 225Ac-DOTA-Anti-CD38 daratumumab monoclonal antibody in combination with fludarabine, melphalan and total marrow and lymphoid irradiation (TMLI) as conditioning treatment for donor stem cell transplant in patients wi…

    Stage
    Phase 1
    Ages
    18 to 70
    Site
    City of Hope Medical Center, Duarte, California
    Run by
    City of Hope Medical Center

    See if you can join NCT06287944 on ClinicalTrials.gov

  4. A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant

    This phase Ib trial tests the safety, side effects, and how well cytomegalovirus (CMV)-modified vaccinia Ankara (MVA) Triplex vaccine works in enhancing CMV-specific immunity and preventing CMV viremia in patients undergoing haploidentical hematopoietic stem cell transplant. Haploidentical stem cel…

    Stage
    Phase 1
    Ages
    18 to 75
    Site
    City of Hope Medical Center, Duarte, California
    Locations
    3 in total
    Run by
    City of Hope Medical Center

    See if you can join NCT07020533 on ClinicalTrials.gov

  5. Tagraxofusp and Azacitidine for Maintenance Treatment in Patients With CD123 Positive AML and MDS Following Donor Hematopoietic Cell Transplant

    This phase Ib trial tests the safety, side effects, best dose and effectiveness of tagraxofusp in combination with azacitidine as maintenance therapy in treating patients with CD123 positive acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) after a donor (allogeneic) hematopoietic cel…

    Stage
    Phase 1
    Ages
    18 to 75
    Site
    City of Hope Medical Center, Duarte, California
    Run by
    City of Hope Medical Center

    See if you can join NCT06498973 on ClinicalTrials.gov

  6. Emapalumab With Post-Transplant Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Graft-versus-Host Disease After Donor Reduced-Intensity Hematopoietic Cell Transplant

    This phase I trial tests the safety, side effects and effectiveness of emapalumab with post-transplant cyclophosphamide, tacrolimus, and mycophenolate mofetil in preventing graft-versus-host disease (GVHD) in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) after reduced…

    Stage
    Phase 1
    Ages
    18 to 75
    Site
    City of Hope Medical Center, Duarte, California
    Run by
    City of Hope Medical Center

    See if you can join NCT06996119 on ClinicalTrials.gov

  7. Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation After Reduced Intensity Conditioning

    This phase II trial studies how well vedolizumab plus post-transplant cyclophosphamide (PTCy) and short course tacrolimus work for the prevention of graft versus host disease (GVHD) in patients undergoing allogeneic hematopoietic cell transplantation (HCT) after reduced intensity conditioning. Allo…

    Stage
    Phase 2
    Ages
    18 to 80
    Site
    City of Hope Medical Center, Duarte, California
    Run by
    City of Hope Medical Center

    See if you can join NCT06815003 on ClinicalTrials.gov

  8. SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

    This research study is studying a drug as a possible treatment for diagnosis of AML, BPDCN and high-risk MDS. The interventions involved in this study are: * SL-401 * Azacitidine * Venetoclax

    Stage
    Phase 1
    Ages
    18 and older
    Site
    City of Hope, Duarte, California
    Locations
    3 in total
    Run by
    Dana-Farber Cancer Institute

    See if you can join NCT03113643 on ClinicalTrials.gov

  9. Orca-T Following Chemotherapy and Total Marrow and Lymphoid Irradiation for the Treatment of Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia or Myelodysplastic Syndrome

    This phase I trial tests the side effects and best dose of total marrow lymphoid irradiation along with chemotherapy, with fludarabine and melphalan, with or without thiotepa, in combination with Orca-T cells for patients with acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) or myel…

    Stage
    Phase 1
    Ages
    60 and older
    Site
    City of Hope Medical Center, Duarte, California
    Run by
    City of Hope Medical Center

    See if you can join NCT06195891 on ClinicalTrials.gov

  10. CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant

    This phase II clinical trial tests how well the cytomegalovirus-modified vaccinica Ankara (CMV-MVA) Triplex vaccine given to human leukocyte antigens (HLA) matched related stem cell donors works to prevent cytomegalovirus (CMV) infection in patients undergoing hematopoietic stem cell transplant. Th…

    Stage
    Phase 2
    Ages
    18 to 75
    Site
    City of Hope Medical Center, Duarte, California
    Locations
    3 in total
    Run by
    City of Hope Medical Center

    See if you can join NCT06059391 on ClinicalTrials.gov

  11. Olutasidenib for the Treatment of Patients With IDH1 Mutated AML, MDS or CMML After Donor Hematopoietic Cell Transplant

    This phase I trial tests the safety, side effects, and effectiveness of olutasidenib in preventing the return of disease (relapse) in patients who have undergone donor (allogeneic) hematopoietic cell transplant for acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or chronic myelomonocy…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    City of Hope Medical Center, Duarte, California
    Locations
    2 in total
    Run by
    City of Hope Medical Center

    See if you can join NCT06543381 on ClinicalTrials.gov

  12. Ruxolitinib With Tacrolimus and Methotrexate for the Prevention of Graft Versus Host Disease in Pediatric and Young Adult Patients Undergoing Allogeneic Hematopoietic Cell Transplant for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome

    This phase II trial tests how well ruxolitinib with tacrolimus and methotrexate work to prevent the development of graft versus host disease in pediatric and young adult patients undergoing allogeneic hematopoietic cell transplant for acute myeloid leukemia, acute lymphoblastic leukemia, or myelody…

    Stage
    Phase 2
    Ages
    2 to 22
    Site
    City of Hope Medical Center, Duarte, California
    Run by
    City of Hope Medical Center

    See if you can join NCT06128070 on ClinicalTrials.gov

  13. A Study of BTX-A51 in People With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

    This is an open-label, dose escalation study to evaluate the safety, toxicity, and pharmacokinetics (PK) as well as preliminary efficacy of BTX-A51 capsules in participants with relapsed or refractory acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS). The study will be done i…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    City of Hope National Medical Center, Duarte, California
    Locations
    3 in total
    Run by
    Edgewood Oncology Inc.

    See if you can join NCT04243785 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.